BD-737
| BD-737 | |
|---|---|
| [[File:|frameless|220px|alt=|Chemical structure of BD-737]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
BD-737 is a chemical compound that acts as a selective agonist for the sigma-1 receptor, a type of sigma receptor that is involved in various neurological processes. This compound has been studied for its potential therapeutic effects in the treatment of neurological disorders and psychiatric conditions.
Pharmacology[edit]
BD-737 is known for its high affinity and selectivity towards the sigma-1 receptor, which is a chaperone protein located in the endoplasmic reticulum of cells. The sigma-1 receptor modulates the activity of various ion channels and receptors, influencing neurotransmitter release and neuroplasticity.
Mechanism of Action[edit]
BD-737 binds to the sigma-1 receptor, leading to conformational changes that enhance the receptor's ability to modulate calcium signaling and other cellular processes. This interaction is believed to contribute to its neuroprotective and antidepressant-like effects observed in preclinical studies.
Therapeutic Potential[edit]
Research on BD-737 has suggested potential applications in treating conditions such as depression, schizophrenia, and neurodegenerative diseases like Alzheimer's disease. Its ability to modulate sigma-1 receptor activity may help in alleviating symptoms associated with these disorders.
Research and Development[edit]
BD-737 is primarily used in research settings to explore the role of sigma-1 receptors in the central nervous system. Studies have demonstrated its efficacy in animal models, but further research is needed to determine its safety and effectiveness in humans.
Safety and Toxicology[edit]
As with many investigational compounds, the safety profile of BD-737 is not fully established. Preclinical studies have not reported significant adverse effects, but comprehensive toxicological evaluations are necessary before considering clinical trials.
Also see[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
